Multiple myeloma has long challenged researchers because the disease is not driven only by uncontrolled growth. Its malignant plasma cells must also survive an unusually harsh environment inside the bone marrow, where nutrients, oxygen and growth signals can fluctuate dramatically. A study by Tauro, Li, Sudalagunta and colleagues, published in Nature Communications, identifies the protein Unc-51-like kinase 3, or ULK3, as an important contributor to that survival system. The findings place ULK3 at the intersection of autophagy, cellular stress management and myeloma persistence, pointing to a previously underappreciated vulnerability in a cancer that frequently returns after treatment.
Multiple myeloma develops from abnormal plasma cells, the immune cells responsible for producing antibodies. These cancerous cells accumulate in the bone marrow and release large quantities of immunoglobulins, placing exceptional demands on their protein-production machinery. They must continuously fold, transport and maintain vast numbers of proteins while coping with oxidative stress, metabolic pressure and damage to cellular components. Autophagy, a regulated recycling process, helps cells endure these conditions. During autophagy, portions of the cytoplasm, damaged proteins and defective organelles are enclosed in double-membrane structures called autophagosomes. These structures then fuse with lysosomes, where their contents are broken down and recycled.
The new research focuses on ULK3, a member of the Unc-51-like kinase family. Kinases are enzymes that control other proteins by adding phosphate groups to them, thereby changing their activity, location or stability. ULK proteins are widely recognized as early regulators of autophagy, helping cells decide when to initiate the formation of autophagosomes. ULK1 and ULK2 have traditionally received most of the attention in this pathway, while ULK3 has remained less clearly defined. The study now links ULK3 to the biology of multiple myeloma, suggesting that this kinase is not merely a redundant relative of other autophagy regulators but may perform a meaningful function in malignant plasma cells.
The importance of this connection lies in the way myeloma cells use autophagy as a survival strategy. Autophagy is not automatically beneficial or harmful; its effect depends on the cell and its circumstances. In healthy tissues, it can remove damaged mitochondria, eliminate toxic protein aggregates and preserve energy during starvation. In cancer, the same recycling system can help tumor cells tolerate chemotherapy, nutrient deprivation and rapid growth. For plasma-cell cancers, which are burdened by intense protein synthesis, autophagy may be especially valuable because it helps maintain internal quality control and supplies metabolic building blocks when external resources are limited.
According to the study, ULK3 contributes to the ability of multiple myeloma cells to sustain autophagy and remain viable. This finding implies that ULK3 may help coordinate the early steps of the autophagic response or support the broader cellular machinery required to complete it. When such a regulatory node is weakened, cancer cells may lose their capacity to clear damaged material and respond to stress. The result can be an accumulation of defective proteins, impaired organelle function and increased susceptibility to cell death. In myeloma, where the production of abnormal or excessive proteins is already a central feature of the disease, disruption of this balance could be particularly damaging.
The work also offers a biological explanation for why targeting autophagy may affect myeloma survival. Blocking the pathway can produce a form of “stress overload”: cellular waste accumulates, energy production becomes less efficient and damaged components remain in the cytoplasm. At the same time, cancer cells may be unable to reduce their protein burden or adapt to hostile conditions. ULK3 therefore represents a potential control point before the later stages of autophagosome formation and lysosomal degradation. Targeting an early regulator could, in principle, interrupt the process before malignant cells can activate several downstream protective mechanisms.
However, the study does not imply that ULK3 is a universal cancer switch or that a single intervention will eliminate multiple myeloma. Autophagy is a complex network with overlapping regulators, feedback loops and cell-specific effects. If one ULK family member is inhibited, cancer cells may compensate through alternative signaling routes, including pathways controlled by ULK1, ULK2, nutrient-sensing complexes or stress-responsive kinases. The therapeutic challenge will be to determine whether ULK3 can be blocked selectively enough to harm myeloma cells without causing unacceptable injury to normal tissues that also depend on autophagy for long-term maintenance.
The findings are especially relevant to the search for treatments that can overcome drug resistance. Modern myeloma therapy commonly combines agents that attack different aspects of plasma-cell biology, yet many patients eventually relapse because residual malignant cells adapt and survive. A therapy directed at ULK3 could potentially be evaluated alongside established treatments, with the goal of preventing cancer cells from using autophagy as a backup survival program. Such combinations would require careful testing, because some drugs may increase cellular stress and thereby make autophagy inhibition more powerful, while others could trigger compensatory responses that reduce its effect.
Before ULK3 can become a clinical target, researchers will need to clarify how its activity is controlled, which molecular partners it engages and whether its dependence is strongest in particular genetic or metabolic subtypes of myeloma. Biomarkers will also be essential. Measuring ULK3 abundance or activity alone may not predict response if the pathway is governed by several interacting proteins. Investigators may instead need to examine autophagic flux—the rate at which cellular material moves through the pathway—along with protein-folding stress, mitochondrial condition and the molecular features of each patient’s tumor. The study’s central message is therefore both mechanistic and practical: ULK3 helps myeloma cells survive, and understanding that dependence could reveal a new route for weakening a disease that remains difficult to cure.
Subject of Research: Unc-51-like kinase 3 (ULK3), autophagy, cell survival and multiple myeloma
Article Title: Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma
Article References: Tauro, M., Li, T., Sudalagunta, P.R. et al. “Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76711-0
Image Credits: AI Generated
DOI: 10.1038/s41467-026-76711-0
Keywords: ULK3, autophagy, multiple myeloma, plasma cells, cancer cell survival, cellular stress, kinase signaling, therapeutic targets
Tags: autophagosome formationautophagy in cancer cellsbone marrow microenvironmentcancer cell survival mechanismscancer treatment resistancecellular stress responseMultiple Myelomaoxidative stress managementprotein recycling in cancerrole of ULK3 in autophagytherapeutic vulnerabilities in multiple myelomaULK3 protein
